BIPLA Annual Symposium: Enablement after Amgen

The Boston Intellectual Property Law Association (BIPLA) is hosting its Annual Symposium titled "Enablement after Amgen." This event will focus on the implications of the U.S. Supreme Court's decision in Amgen v. Sanofi, particularly concerning the enablement requirement under 35 U.S.C. § 112(a) as it applies to patent claims directed at antibodies.

Key topics include an in-depth analysis of the Amgen v. Sanofi case, the Supreme Court's ruling, and the subsequent guidance issued by the U.S. Patent and Trademark Office (USPTO). The symposium will feature a panel discussion moderated by Timothy V. Fisher, a patent attorney and electrical engineer from Pierce Atwood. Panelists Amy Mahan and Matthew Pearson, who represented opposing sides in the case, will share insights into the case's history, the Court's decision, and practical tips for practitioners.

Attendees will have opportunities to engage with leading experts in the field, participate in discussions on the latest developments in patent law, and network with peers. The event is designed for intellectual property professionals, patent attorneys, and legal scholars interested in the evolving landscape of patent enablement requirements.

The symposium is scheduled for April 10, 2024. For registration details and further information, please visit the BIPLA website.